Ajinomoto Bio-Pharma Services

ABOUT AJINOMOTO BIO-PHARMA SERVICES

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Belgium, United States, Japan and India, providing comprehensive process development services, cGMP manufacturing and drug product fill finish services of small molecule and biologic APIs and intermediates. We offer a broad range of innovative platforms and capabilities to rapidly scale from clinical and pilot programs to commercial quantities, including: Corynex protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients’ needs.

Ajinomoto Bio-Pharma Services offers a range capabilities through its facilities around the world. Our facilities in Belgium, Japan, and India focus on conventional small molecule API and intermediate production. The focus at our California, USA facility is on large molecule and ADC manufacturing and aseptic fill finish services. Our Osaka, Japan facilities focus on oligonucleotide synthesis.

Our expertise and extensive knowledge of international requirements help assure your product will meet the highest possible quality standards. Our goal is to deliver quality product and personalized service, while providing flexibility and guidance to help our clients achieve their goals in a timely and efficient, cost-effective manner.

Ajinomoto Bio-Pharma Services is a member of the Ajinomoto Group companies, a global company focused on the research, development, and manufacture of high quality products for the pharmaceutical, specialty chemical, nutraceutical, sports nutrition, and health & beauty industries, as well as food seasonings and consumer food products.

VIDEOS AND WEBINARS

You Had Me At Flow: The Shift From Batch To Continuous

The pharmaceutical industry is undergoing a transformative shift from batch to continuous flow processes, enabling enhanced efficiency and safety as well as improved sustainability.
Ajinomoto Bio-Pharma Services Capacity Update May 2024: Small Molecule APl and HPAPI Development

Our experts delve into the advancements in our development and manufacturing capabilities for HPAPI, clinical development, and late stage projects.
Breaking Bad Manufacturing Habits: Attaining Sustainable API Production

Sustainability is a growing issue in the pharmaceutical industry. Review strategies for reducing your carbon footprint and learn how the right CDMO can help drive the sustainable manufacture of APIs.
Ajinomoto Bio-Pharma Services Capacity Update February 2024: Small Molecule

Explore the recent expansions of Ajinomoto BPS. Our experts delve into the advancements in our development and manufacturing capabilities for HPAPI, clinical development, and late-stage projects.
File First In Europe, Then The U.S.?

Karla Knower, Global Head of Regulatory Affairs, Paradigm Biopharmaceuticals, answers a challenging question from an attendee at a recent Outsourced Pharma Live.
Small Molecule APIs: From Pre-RSM To Final API

As a leader in small molecule manufacturing, Ajinomoto Bio-Pharma Services has over 40 years of experience providing high quality APIs and intermediates for pharmaceutical companies throughout the world.
Aji Bio-Pharma and Catalisti

The HANU, a new photo-flow reactor, provides better process control, less risk in hazardous chemistry, less solvent use, and is better for the environment.
From Bench To Batch: Strategies For Scaling HPAPI Production

Highly potent materials bring additional challenges to manufacturing processes. Examine considerations for optimizing HPAPI production methods to reduce risk and deliver therapies to patients with speed.
The Paradigm Shift To Continuous Flow Processes: A Holistic View

A clear increase in continuous flow processes has emerged over the past decade, thanks to the commercialization of preparative flow reactor units.
Are You Protecting Employees During HPAPI Manufacturing?

Tom Evans, MS, CMMS discusses the planning, resources, and capabilities necessary to effectively produce a client’s highly potent active pharmaceutical ingredient (HPAPI) therapeutic.